MiMedx Group (NASDAQ:MDXG) Shares Down 6.4% – Time to Sell?

Posted by Stanley Muller on Oct 23rd, 2026

Shares of MiMedx Group, Inc (NASDAQ:MDXG – Get Free Report) traded down 6.4% on Wednesday. The stock traded as low as $4.03 and last traded at $3.9610. Approximately 300,430 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 1,281,910 shares. The stock had previously closed at $4.23.

Analyst Ratings Changes

Several equities research analysts recently commented on MDXG shares. Wall Street Zen raised MiMedx Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Craig Hallum boosted their target price on MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Weiss Ratings upgraded shares of MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 27th. Seaport Research Partners downgraded MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of MiMedx Group in a research note on Tuesday, September 15th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, MiMedx Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.57.

View Our Latest Stock Analysis on MDXG

MiMedx Group Stock Up 5.1%

The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The business has a 50-day moving average of $4.54 and a 200 day moving average of $4.08. The company has a market capitalization of $572.84 million, a PE ratio of 98.27 and a beta of 1.18.

MiMedx Group (NASDAQ:MDXG – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. Equities research analysts predict that MiMedx Group, Inc will post -0.10 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MDXG. Punch & Associates Investment Management Inc. purchased a new position in MiMedx Group during the 2nd quarter valued at $7,924,000. Squarepoint Ops LLC increased its position in shares of MiMedx Group by 73.7% during the second quarter. Squarepoint Ops LLC now owns 571,930 shares of the company’s stock worth $2,202,000 after acquiring an additional 242,714 shares during the period. Paradigm Capital Management Inc. NY purchased a new position in MiMedx Group during the 2nd quarter worth $15,681,000. Nantahala Capital Management LLC purchased a new position in shares of MiMedx Group during the second quarter valued at $18,355,075. Finally, Bank of New York Mellon Corp purchased a new position in MiMedx Group during the 2nd quarter valued at about $1,629,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.